Connect
← Return to Aromatase Inhibitors: Did you decide to go on them or not?
Discussion
Aromatase Inhibitors: Did you decide to go on them or not?
Breast Cancer | Last Active: May 12, 2023 | Replies (1190)Comment receiving replies
Here is the excerpted text from breastcancer.org:
For invasive:
"So, the Oncotype DX Breast Recurrence Score Test is both a prognostic test, since it provides more information about how likely (or unlikely) the breast cancer is to come back, and a predictive test, since it predicts the likelihood of benefit from chemotherapy or radiation therapy treatment. Studies have shown that Oncotype DX Breast Recurrence Score Test is useful for both purposes."
For DCIS:
(After the Oncotype) "Radiation therapy may be recommended for some women. Doctors aren’t always sure which women will benefit from radiation therapy."
I was surprised. Back in 2014 Radiation was not mentioned in the context of the Oncotype, only pathology. @callalloo are you saying this is mistaken?
Replies to "Here is the excerpted text from breastcancer.org: For invasive: "So, the Oncotype DX Breast Recurrence Score..."
I took the questions about Oncotype DX to Dr. Sandhya Pruthi at the Mayo Clinic Breast Clinic. She confirmed that the "Oncotype DX test is not used to predict the benefit radiation. The Oncotype DX Breast DCIS Score test can help determine if radiation is indicated. Patients with DCIS- ductal carcinoma in-situ- may have this test ordered by their oncologist or radiation oncologist to determine if radiation is indicated."
Here is further information:
- What is the Oncotype DX® test, and what makes it unique? https://www.oncotypeiq.com/en-CA/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test
"The Oncotype DX Breast Recurrence Score® test has been developed for patients with early-stage HR+, HER2- breast cancer to:
- Precisely identify those patients who will and will not benefit from adjuvant chemotherapy
- Determine the magnitude of chemotherapy benefit
- Provide an individual’s risk of distant recurrence"
- About the Oncotype DX Breast DCIS Score test https://www.oncotypeiq.com/en-US/breast-cancer/patients-and-caregivers/stage-0-dcis/about-the-test
Connect
Exactly! This is totally wrong.. Breastcancer.org is still saying, which is completely flat out incorrect, that the OncotypeDX can yield ANY info upon which to help base a radiation decision.
Oncotype doesn't have a test that addresses radiatiion. Yet, according to the senior science guy I talked to, doctors and patients are seeing this misstatement of fact and thinking it's true. The OncotypeDX is strictly designed to yield a 'likely benefit versus risk' anslysis of chemo for the person whose 21 genes the test looked at.
Virtually zero inferences can be drawn about radiation benefits for that specific person from the OncotypeDX. [There is also an Oncotype Breast Cancer Assay, which doesn't address chemo or radiation either.]
I've written to Breastcancer.org several times to correct their misunderstanding to no avail. The problem with mistruths on the internet is that they have a very long shelf life. It's impossible to get them off of the zillion other websites that just cut-and-paste stuff to their own.